178 related articles for article (PubMed ID: 19331811)
1. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes.
Pentassuglia L; Graf M; Lane H; Kuramochi Y; Cote G; Timolati F; Sawyer DB; Zuppinger C; Suter TM
Exp Cell Res; 2009 Apr; 315(7):1302-12. PubMed ID: 19331811
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes.
Pentassuglia L; Timolati F; Seifriz F; Abudukadier K; Suter TM; Zuppinger C
Exp Cell Res; 2007 May; 313(8):1588-601. PubMed ID: 17400210
[TBL] [Abstract][Full Text] [Related]
3. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
4. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.
Timolati F; Ott D; Pentassuglia L; Giraud MN; Perriard JC; Suter TM; Zuppinger C
J Mol Cell Cardiol; 2006 Nov; 41(5):845-54. PubMed ID: 17005195
[TBL] [Abstract][Full Text] [Related]
5. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways.
Gordon LI; Burke MA; Singh AT; Prachand S; Lieberman ED; Sun L; Naik TJ; Prasad SV; Ardehali H
J Biol Chem; 2009 Jan; 284(4):2080-7. PubMed ID: 19017630
[TBL] [Abstract][Full Text] [Related]
7. Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: implications for anthracycline cardiomyopathy.
Chen B; Zhong L; Roush SF; Pentassuglia L; Peng X; Samaras S; Davidson JM; Sawyer DB; Lim CC
PLoS One; 2012; 7(4):e35743. PubMed ID: 22532871
[TBL] [Abstract][Full Text] [Related]
8. MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte.
Wan GX; Cheng L; Qin HL; Zhang YZ; Wang LY; Zhang YG
Cardiovasc Toxicol; 2019 Jun; 19(3):264-275. PubMed ID: 30535663
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
10. The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2013 Mar; 13(1):33-47. PubMed ID: 22948710
[TBL] [Abstract][Full Text] [Related]
11. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
Seemann I; te Poele JA; Song JY; Hoving S; Russell NS; Stewart FA
Breast Cancer Res Treat; 2013 Oct; 141(3):385-95. PubMed ID: 24091769
[TBL] [Abstract][Full Text] [Related]
12. Zinc pyrithione inhibits caspase-3 activity, promotes ErbB1-ErbB2 heterodimerization and suppresses ErbB2 downregulation in cardiomyocytes subjected to ischemia/reperfusion.
Bodiga VL; Thokala S; Vemuri PK; Bodiga S
J Inorg Biochem; 2015 Dec; 153():49-59. PubMed ID: 26436560
[TBL] [Abstract][Full Text] [Related]
13. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt.
Fukazawa R; Miller TA; Kuramochi Y; Frantz S; Kim YD; Marchionni MA; Kelly RA; Sawyer DB
J Mol Cell Cardiol; 2003 Dec; 35(12):1473-9. PubMed ID: 14654373
[TBL] [Abstract][Full Text] [Related]
14. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
16. Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of Erbb2 signaling as a remodeling factor of myofibril architecture.
Reischauer S; Arnaout R; Ramadass R; Stainier DY
Circ Res; 2014 Oct; 115(10):845-56. PubMed ID: 25228389
[TBL] [Abstract][Full Text] [Related]
17. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
Grabinski N; Ewald F
Invest New Drugs; 2014 Dec; 32(6):1096-104. PubMed ID: 25081321
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
20. Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells.
Nguyen HT; Adam RM; Bride SH; Park JM; Peters CA; Freeman MR
Am J Physiol Cell Physiol; 2000 Oct; 279(4):C1155-67. PubMed ID: 11003596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
